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Abstract
Objective—To determine which children with urinary tract infection (UTI) are likely to have 
pathogens resistant to narrow-spectrum antimicrobials.
Study design—Children, 2 to 71 months of age (n=769) enrolled in the RIVUR or CUTIE 
studies were included. We used logistic regression models to test the associations between 
demographic and clinical characteristics and resistance to narrow-spectrum antimicrobials.
Results—Of the included patients, 91% were female and 76% had vesicoureteral reflux. The risk 
of resistance to narrow-spectrum antibiotics in uncircumcised males was approximately 3 times 
that of females (OR=3.1; 95% CI: 1.4—6.7); in children with bladder bowel dysfunction (BBD) 
the risk was 2 times that of children with normal function (OR=2.2; 95% CI: 1.2—4.1). Children 
who had received one course of antibiotics during the past 6 months also had higher odds of 
harboring resistant organisms (OR=1.6; 95% CI: 1.1—2.3). Hispanic children had higher odds of 
harboring pathogens resistant to some narrow-spectrum antimicrobials.
Conclusions—Uncircumcised males, Hispanic children, children with BBD, and children who 
received one course of antibiotics in the past 6 months were more likely to have a UTI caused by 
pathogens resistant to one or more narrow-spectrum antimicrobials.
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The majority of cases of community-acquired urinary tract infection (UTI) are treated (72%)
(1) with narrow spectrum antimicrobials, defined here as first generation cephalosporins, 
trimethoprim sulfamethoxazole, nitrofurantoin, and amoxicillin. However, emerging 
resistance among uropathogens threatens to limit the efficacy of these antimicrobials. In 
order to promote continued judicious use of narrow-spectrum antimicrobials, it would be 
important to determine characteristics of children who can continue to safely and 
appropriately receive these agents. Available data suggest that young age,(2, 3) female sex,
(2, 4) black race,(5) and recent exposure to antimicrobials(5) may be associated with 
antimicrobial resistance. However, the majority of these data were obtained through 
retrospective analyses of cross-sectional databases assembled for other reasons, and many of 
them lacked detailed descriptions of patients.
In this investigation, we used data from two prospective, multicenter studies, in which 
clinical and demographic characteristics were carefully documented, to determine if patient 
characteristics could be used to predict resistance to narrow-spectrum antimicrobials. 
Participant characteristics linked with resistance were further investigated using a mediation 
model. In these models we assessed whether pathogen type (E. coli vs. non- E. coli) could 
explain any observed associations between patient characteristics and resistance.
METHODS
Our database included 607 children with vesicoureteral reflux (VUR) enrolled in the 
Randomized Intervention for Children with Vesicoureteral Reflux (RIVUR) trial and 195 
children without VUR enrolled in the parallel observational Careful Urinary Tract Infection 
Evaluation (CUTIE) study. We excluded 33 children with missing data (organism, voiding 
cystourethrogram, race, ethnicity, antibiotic treatment, or presence of BBD), resulting in a 
sample of 769 children. Methods of the RIVUR and CUTIE studies have been previously 
reported.(6–8) Briefly, the RIVUR trial enrolled children 2 to 71 months of age presenting 
with a first or second febrile or symptomatic UTI from both primary and subspecialty care 
settings at clinical trial centers throughout North America. Children who were found to have 
grades I to IV VUR after their index UTI were enrolled in the RIVUR trial. Children with a 
first or second UTI but without VUR were enrolled in the CUTIE study at 3 of the 19 
participating RIVUR sites (Pittsburgh, Philadelphia and Washington, DC). None of the 
children enrolled in either study were receiving antimicrobial prophylaxis for VUR at the 
time of diagnosis of the index UTI. BBD, which refers to an abnormal pattern of elimination 
characterized by bowel and bladder incontinence and/or withholding, was assessed at the 
time of enrollment in both studies. The reported research has been approved an the 
institutional review board.
Resistance patterns of urinary pathogens were reported according to each laboratory’s 
protocol. Although all laboratories were certified through the Clinical Laboratory 
Improvement Amendments (CLIA) process, not all laboratories tested for the same 
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antimicrobials. Accordingly, the total number of specimens differs for each antimicrobial. 
For the purposes of this analysis, we combined intermediate and full resistance. We grouped 
antimicrobials according to class because pathogens generally exhibit the same resistance 
profile for all antimicrobials in a given class (i.e., a pathogen will either be resistant or 
sensitive to all first generation cephalosporins tested). If a pathogen was resistant to any 
member of a class, it was classified as resistant. First-generation cephalosporins included 
cefadroxil, cefazolin and cephalexin; second-generation cephalosporins included cefotetan, 
cefoxitin, cefuroxime; third-generation cephalosporins included cefotaxime, cefixime, 
ceftazidime and ceftriaxone; and quinolones included ciprofloxacin, gemifloxacin, 
levofloxacin and norfloxacin. We did not include cephalothin in the first-generation 
cephalosporin group because, in our data and in other studies, resistance to cephalothin is 
inconsistent with resistance to other first-generation cephalosporins.(2) We grouped 
amoxicillin and ampicillin together.
We used logistic regression models to test the independent association between demographic 
and clinical characteristics and resistance to narrow-spectrum antimicrobials. The following 
baseline predictors were considered: age, site (grouped into 6 administrative sites), 
organism, sex, race, ethnicity, presence of BBD, use of antimicrobials in the preceding 6 
months for infections other than UTIs, number of previous UTIs, type of index UTI (febrile 
vs. afebrile), and symptom duration (0 days, 1–2 days, 3–4 days, 5+ days, unknown). Age 
was categorized as 2–11 months, 12–23 months, 24–35 months, and 36–72 months. 
Unadjusted effects for the following symptoms were also considered: suprapubic/abdominal/
flank pain or tenderness, urinary urgency, urinary frequency, urinary hesitancy, dysuria, and 
foul-smelling urine. Because vesicoureteral status is unknown at the time of diagnosis, we 
did not include this variable in our prediction model. We did, however, separately examine 
whether presence or grade of VUR was associated with resistance to narrow-spectrum 
antimicrobials.
To explore whether the relationship between characteristics and resistance to narrow-
spectrum antimicrobials was mediated by organism type, we used the approach suggested by 
Imai, Keele, and Tingly.(9)
RESULTS
Table I describes clinical and demographic characteristics of the sample. Of 769 children, 
703 (91%) were female and 596 (78%) were white; 49% of the cohort was aged 2–11 
months; 699 (91%) had index UTIs caused by E. coli. Children enrolled in the CUTIE study 
were older (30% vs. 20% age 36–72 months), more likely to be non-white (33% vs. 19%) 
and Hispanic (20% vs. 12%).
Of 889 instances in which two or more antimicrobials of the same class were tested on the 
same isolate, we identified 16 discrepancies (1.8%) in antimicrobial resistance within a class 
(7 among second-generation cephalosporins, 2 among third-generation cephalosporins and 7 
among quinolones). As previously noted, we assumed resistance to a class of antimicrobials 
when resistance was observed for any member of the class.
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The proportion of children with pathogens sensitive to the various classes of antimicrobials 
is shown in the Figure. Overall, sensitivity to amoxicillin was low, with little difference 
noted between E. coli 55%) and organisms other than E. coli 61%). Sensitivity to first-
generation cephalosporins and nitrofurantoin was generally high among E. coli pathogens 
(93% and 99%, respectively), but not so for non-E. coli pathogens (72% and 40%, 
respectively). The opposite was the case for trimethoprim-sulfamethoxazole with E. coli 
pathogens exhibiting lower sensitivity than non-E. coli pathogens (81% vs. 98%, 
respectively). Sensitivity to second-generation cephalosporins, third-generation 
cephalosporins, gentamicin, tobramycin and quinolones was >90% for both E. coli and non-
E. coli organisms and considerably higher than sensitivity to amoxicillin clavulanate.
Predictors of resistance to narrow-spectrum antimicrobials
The risk of resistance (Table II) in uncircumcised males was approximately 3 times that of 
females for first-generation cephalosporin (OR=3.2; 95% CI=1.2—8.8) and amoxicillin 
(OR=3.2; 95% CI=1.5—6.7). Receipt of one dose of antibiotics in the past 6 months also 
increased the odds of resistance to first-generation cephalosporin (OR=2.1; 95% CI=1.1—
4.0) and amoxicillin (OR=1.5; 95% CI=1.0—2.1), but receipt of 2 or more courses of 
antimicrobials did not modify the odds of resistance to narrow-spectrum antimicrobials. 
Hispanic children had higher odds of harboring pathogens resistant to trimethoprim-
sulfamethoxazole (OR=2.5, 95% CI=1.5—4.1, p<.0001) and exhibited the same trend with 
other antimicrobials. Particularly high rates of resistance to amoxicillin (66%) and 
trimethoprim-sulfamethoxazole (40%) were found in children from Washington D.C. 
Presence of BBD was associated with resistant pathogens for 2 of the 4 antibiotics. Age, 
race, and fever were not associated with resistant uropathogens. We examined rates of 
resistance by VUR grade (grouped as 0, 1–2, 3–4) for antimicrobials listed in Table II. Only 
nitrofurantoin had a significant difference in resistance by VUR grade (4% in VUR grade 0, 
4% in VUR grades 1–2, and 9% in VUR grades 3–4, chi-square p-value=0.04). Rates of 
resistance for other antimicrobials did not differ by VUR grade (p≥0.31).
The associations between sex/circumcision, BBD, and Hispanic ethnicity and resistance to 
trimethoprim sulfamethoxazole, amoxicillin, or first generation cephalosporins were 
consistent after adjusting for pathogen type (data not shown). This indicates that pathogen 
type did not mediate any of the associations between characteristics and resistance to these 3 
antibiotics. Resistance to nitrofurantoin, however, was dominated by the effect of primary 
pathogen (OR=690.3, 95% CI=140.6—3389.5).
DISCUSSION
The desire to use narrow-spectrum antimicrobials relates to cost, safety and concerns 
regarding antimicrobial resistance. Accordingly, the ability to determine accurately the risk 
of resistance to narrow-spectrum antimicrobials is desirable. This information may allow 
clinicians to use clinical factors available at the time of diagnosis to select effective 
antimicrobials more judiciously; children with risk factors for resistance should be treated 
with broader-spectrum agents, thus potentially reducing the incidence of treatment failure 
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and scarring,(10–13), and children with low risk could safely be treated with narrow-
spectrum agents.
We identified predictors of resistant pathogens to the most frequently used narrow-spectrum 
antimicrobials. Uncircumcised males, Hispanic children, and children with BBD were more 
likely to have a UTI caused by pathogens resistant to one or more narrow-spectrum 
antimicrobials. The higher rates of resistance for some antimicrobials in children with BBD 
are intriguing. Perhaps, children with BBD, who may incompletely empty their bladders, 
have UTIs caused by bacterial strains with different virulence factors and different 
resistance patterns. The reasons for the higher rates of resistance in Washington D.C. are not 
clear. Similar to previous reports,(5) we found that the use of antimicrobials during the past 
6 months increased the risk of resistance to narrow-spectrum antimicrobials. However, our 
data showed an inconsistent dose-response trend, i.e., more exposure to antibiotics did not 
result in increased likelihood of resistance. Unlike one previous study,(5) we did not find 
that age <1 year, female sex, or black race were risk factors for resistance to narrow-
spectrum antimicrobials.
Resistance to amoxicillin was high; approximately 40% of children had organisms resistant 
to this antimicrobial. Accordingly, use of the antimicrobial for the treatment of UTI is not 
appropriate. Of note, resistance to amoxicillin clavulanate was also relatively high in our 
sample; 17.5% of children had organisms that were resistant to this antimicrobial (Figure). 
Accordingly, this broad-spectrum antimicrobial is not an ideal choice for children who have 
risk factors for resistance to narrow-spectrum antimicrobials; a second or third generation 
cephalosporin would be a more appropriate choice in such children.
We investigated possible mediation of resistance by pathogen type. We found that for all 
narrow-spectrum antibiotics except nitrofurantoin, resistance was largely independent of 
pathogen type. In contrast, resistance to nitrofurantoin was mediated by pathogen type; 
circumcised males, Hispanic children, and children with an afebrile UTI were more likely to 
have infections with organisms other than E. coli, and because of this exhibited resistance to 
nitrofurantoin.
Based on our results we would treat children with a high likelihood of renal involvement 
(high fever with or without back pain), with a second- or third-generation cephalosporin; the 
predicted probability of resistance to first-generation cephalosporins, trimethoprim 
sulfamethoxazole, amoxicillin is relatively high and the tissue concentrations of 
nitrofurantoin may not be adequate to eradicate the causative organism. In contrast, in an 
afebrile child with low risk of renal involvement, a first-generation cephalosporin would be 
considered as the most appropriate option; the predicted probability of resistance to 
trimethoprim sulfamethoxazole and amoxicillin are relatively high and nitrofurantoin needs 
to be given more frequently and is more likely to cause gastrointestinal symptoms.
This report has some limitations. Different local laboratories were involved and they did not 
always test for resistance to the same antibiotics. Nevertheless, all laboratories were certified 
CLIA. Additionally, children participating in the RIVUR and CUTIE studies are not 
representative of all children with UTI; for example, the majority of our participants had 
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VUR. However, with one exception (nitrofurantoin) the presence of VUR was not 
associated with resistance to narrow-spectrum antimicrobials.
Importantly, our results are not meant to replace the use of local antibiograms. Rather our 
goal was to explore generalizable risk factors for resistance. If a local antibiogram is 
available, especially if it is restricted to ambulatory,(14, 15) pediatric patients,(16) it should 
be used to guide therapy. Clinicians treating children with UTI can use these data to more 
judiciously select children who can appropriately receive narrow-spectrum antimicrobials.
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Figure 1. 
Proportion of pathogens susceptible to each class of antibiotic
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Table 1
Demographic and clinical characteristics of children with urinary tract infection
Characteristic Total (n=769)
N (%)
Age (months)
    2–11 374 (49)
    12–23 136 (18)
    24–35 89 (12)
    36–72 170 (22)
Sex
    Female 703 (91)
    Uncircumcised male 45 (6)
    Circumcised male 21 (3)
Race
    White 596 (78)
    Non-White 173 (22)
Ethnicity
    Hispanic 106 (14)
    Non-Hispanic 663 (86)
Vesicoureteral reflux
    No vesicoureteral reflux 186 (24)
    Vesicoureteral reflux grades I-II 314 (41)
    Vesicoureteral reflux grades III-IV 269 (35)
Bladder Bowel Dysfunction
    Yes 95 (12)
    No 84 (11)
    Not toilet trained 590 (77)
Number of prior UTIs
    0 700 (91)
    1 69 (9)
Number of times antimicrobials prescribed in preceding 6 months
    0 399 (52)
    1 229 (30)
    ≥2 141 (18)
J Pediatr. Author manuscript; available in PMC 2017 April 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Shaikh et al. Page 10
Ta
bl
e 
2
Pr
ed
ic
to
rs
 o
f r
es
ist
an
ce
 to
 fr
eq
ue
nt
ly
 u
se
d 
an
tim
ic
ro
bi
al
 a
ge
nt
s i
n 
ch
ild
re
n 
w
ith
 u
rin
ar
y 
tra
ct
 in
fe
ct
io
n
A
ny
 N
ar
ro
w
-s
pe
ct
ru
m
 A
nt
ib
io
tic
(N
=7
55
)
1s
t  
ge
ne
ra
tio
n 
ce
ph
al
os
po
ri
n
(N
=6
59
)
Tr
im
et
ho
pr
im
 su
lfa
m
et
ho
xa
zo
le
(N
=7
25
)
N
itr
of
ur
an
to
in
(N
=7
18
)
A
m
ox
ic
ill
in
(N
=7
29
)
%
R
es
ist
a
n
t
O
dd
s r
at
io
 (C
I)*
P*
% R
es
is
ta
nt
O
dd
s r
at
io
 (C
I)*
P*
% R
es
is
ta
nt
O
dd
s r
at
io
 (C
I)*
P*
%
R
es
ist
a
n
t
O
dd
s r
at
io
 (C
I)*
P*
% R
es
is
ta
nt
O
dd
s r
at
io
 (C
I)*
P*
A
ge
 (m
on
th
s)
 
 
2–
11
52
R
ef
8
R
ef
20
R
ef
5
R
ef
47
R
ef
 
 
12
–2
3
48
0.
89
 (0
.58
, 1
.34
)
0.
57
8
0.
90
 (0
.39
, 2
.04
)
0.
79
23
1.
21
 (0
.72
, 2
.04
)
0.
47
4
0.
81
 (0
.28
, 2
.30
)
0.
69
41
0.
82
 (0
.54
, 1
.26
)
0.
36
 
 
24
–3
5
63
1.
62
 (0
.93
, 2
.81
)
0.
09
8
0.
90
 (0
.30
, 2
.70
)
0.
85
16
0.
84
 (0
.39
, 1
.80
)
0.
65
13
1.
64
 (0
.57
, 4
.72
)
0.
36
48
1.
19
 (0
.69
, 2
.08
)
0.
53
 
 
36
–7
2
47
0.
76
 (0
.36
, 1
.63
)
0.
48
9
0.
79
 (0
.17
, 3
.72
)
0.
76
18
0.
67
 (0
.23
, 2
.00
)
0.
48
4
0.
44
 (0
.08
, 2
.33
)
0.
33
42
0.
94
 (0
.44
, 2
.03
)
0.
88
Se
x
 
 
Fe
m
al
e
50
R
ef
8
R
ef
18
R
ef
5
R
ef
43
R
ef
 
 
U
nc
irc
um
ci
se
d 
M
al
e
77
3.
08
 (1
.41
, 6
.69
)
0.
00
5
19
3.
21
 (1
.16
, 8
.84
)
0.
02
38
1.
94
 (0
.90
, 4
.17
)
0.
09
10
1.
36
 (0
.37
, 5
.04
)
0.
65
73
3.
15
 (1
.50
, 6
.63
)
0.
00
2
 
 
Ci
rc
um
ci
se
d 
M
al
e
60
1.
82
 (0
.71
, 4
.66
)
0.
21
7
1.
12
 (0
.14
, 9
.22
)
0.
92
26
2.
15
 (0
.72
, 6
.44
)
0.
17
6
0.
95
 (0
.11
, 8
.48
)
0.
97
40
0.
94
 (0
.37
, 2
.39
)
0.
89
R
ac
e
 
 
W
hi
te
52
R
ef
8
R
ef
19
R
ef
6
R
ef
46
R
ef
 
 
N
on
-W
hi
te
49
0.
81
 (0
.56
, 1
.17
)
0.
26
9
0.
91
 (0
.46
, 1
.81
)
0.
78
21
0.
95
 (0
.60
, 1
.50
)
0.
82
4
0.
62
 (0
.26
, 1
.50
)
0.
29
43
0.
89
 (0
.62
, 1
.29
)
0.
55
Et
hn
ic
ity
 
 
N
on
-H
isp
an
ic
49
R
ef
8
R
ef
17
R
ef
5
R
ef
43
R
ef
 
 
H
isp
an
ic
65
1.
40
 (0
.87
, 2
.25
)
0.
16
13
1.
53
 (0
.68
, 3
.41
)
0.
30
39
2.
47
 (1
.49
, 4
.11
)
<
0.
00
1
9
2.
29
 (0
.93
, 5
.62
)
0.
07
57
1.
22
 (0
.76
, 1
.95
)
0.
41
Si
te
 
 
Pi
tts
bu
rg
h
46
R
ef
8
R
ef
14
R
ef
6
R
ef
42
R
ef
 
 
Ph
ila
de
lp
hi
a
43
0.
81
 (0
.49
, 1
.33
)
0.
40
9
1.
03
 (0
.39
, 2
.67
)
0.
96
23
1.
54
 (0
.82
, 2
.91
)
0.
18
2
0.
40
 (0
.09
, 1
.87
)
0.
25
34
0.
64
 (0
.37
, 1
.08
)
0.
09
 
 
W
as
hi
ng
to
n
71
2.
19
 (1
.21
, 3
.97
)
0.
01
10
0.
99
 (0
.34
, 2
.88
)
0.
99
40
2.
45
 (1
.27
, 4
.72
)
0.
00
8
6
0.
71
 (0
.20
, 2
.54
)
0.
60
66
2.
08
 (1
.16
, 3
.74
)
0.
01
 
 
B
al
tim
or
e
55
1.
15
 (0
.67
, 1
.96
)
0.
62
6
0.
73
 (0
.23
, 2
.34
)
0.
59
19
1.
10
 (0
.53
, 2
.30
)
0.
80
7
1.
06
 (0
.34
, 3
.27
)
0.
92
47
1.
04
 (0
.61
, 1
.79
)
0.
88
 
 
M
ic
hi
ga
n
50
0.
98
 (0
.60
, 1
.62
)
0.
95
10
1.
18
 (0
.45
, 3
.05
)
0.
74
18
1.
06
 (0
.54
, 2
.07
)
0.
87
9
1.
73
 (0
.64
, 4
.67
)
0.
28
39
0.
71
 (0
.43
, 1
.20
)
0.
20
 
 
N
ew
 Y
or
k
55
1.
19
 (0
.78
, 1
.82
)
0.
43
8
0.
90
 (0
.39
, 2
.05
)
0.
80
20
1.
17
 (0
.66
, 2
.08
)
0.
60
4
0.
66
 (0
.24
, 1
.84
)
0.
43
49
1.
07
 (0
.69
, 1
.65
)
0.
76
J Pediatr. Author manuscript; available in PMC 2017 April 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Shaikh et al. Page 11
A
ny
 N
ar
ro
w
-s
pe
ct
ru
m
 A
nt
ib
io
tic
(N
=7
55
)
1s
t  
ge
ne
ra
tio
n 
ce
ph
al
os
po
ri
n
(N
=6
59
)
Tr
im
et
ho
pr
im
 su
lfa
m
et
ho
xa
zo
le
(N
=7
25
)
N
itr
of
ur
an
to
in
(N
=7
18
)
A
m
ox
ic
ill
in
(N
=7
29
)
%
R
es
ist
a
n
t
O
dd
s r
at
io
 (C
I)*
P*
% R
es
is
ta
nt
O
dd
s r
at
io
 (C
I)*
P*
% R
es
is
ta
nt
O
dd
s r
at
io
 (C
I)*
P*
%
R
es
ist
a
n
t
O
dd
s r
at
io
 (C
I)*
P*
% R
es
is
ta
nt
O
dd
s r
at
io
 (C
I)*
P*
Bl
ad
de
r 
an
d 
bo
w
el
dy
sf
un
ct
io
n
 
 
N
o
40
R
ef
10
R
ef
11
R
ef
6
R
ef
31
R
ef
 
 
Y
es
60
2.
19
 (1
.17
, 4
.12
)
0.
01
9
0.
89
 (0
.29
, 2
.79
)
0.
85
26
2.
69
 (1
.12
, 6
.45
)
0.
03
4
0.
72
 (0
.17
, 2
.96
)
0.
64
55
2.
46
 (1
.27
, 4
.74
)
0.
00
7
 
 
N
ot
 to
ile
t t
ra
in
ed
52
1.
23
 (0
.56
, 2
.69
)
0.
61
8
0.
74
 (0
.15
, 3
.55
)
0.
70
20
1.
02
 (0
.32
, 3
.28
)
0.
98
6
0.
84
 (0
.19
, 3
.72
)
0.
82
45
1.
60
 (0
.71
, 3
.60
)
0.
26
C
ou
rs
es
 o
f
a
n
tim
ic
ro
bi
al
s i
n 
th
e
pr
ec
ed
in
g 
6 
m
on
th
s
 
 
0
49
R
ef
7
R
ef
19
R
ef
6
R
ef
44
R
ef
 
 
1
57
1.
62
 (1
.14
, 2
.30
)
0.
00
8
11
2.
07
 (1
.07
, 4
.02
)
0.
03
24
1.
52
 (0
.97
, 2
.37
)
0.
07
5
0.
90
 (0
.41
, 1
.99
)
0.
79
48
1.
44
 (1
.01
, 2
.07
)
0.
05
 
 
≥2
51
1.
14
 (0
.76
, 1
.70
)
0.
54
9
1.
55
 (0
.71
, 3
.40
)
0.
27
16
0.
94
 (0
.54
, 1
.63
)
0.
82
5
0.
83
 (0
.33
, 2
.07
)
0.
68
43
1.
02
 (0
.68
, 1
.55
)
0.
91
Fe
ve
r
 
 
N
o
61
R
ef
10
R
ef
16
R
ef
11
R
ef
48
R
ef
 
 
Y
es
51
0.
79
 (0
.40
, 1
.56
)
0.
50
8
0.
89
 (0
.28
, 2
.87
)
0.
85
21
1.
68
 (0
.67
, 4
.23
)
0.
27
4
0.
40
 (0
.12
, 1
.28
)
0.
12
45
1.
07
 (0
.54
, 2
.12
)
0.
84
 
 
U
nk
no
w
n
51
0.
87
 (0
.39
, 1
.91
)
0.
72
11
1.
31
 (0
.33
, 5
.20
)
0.
70
12
1.
00
 (0
.32
, 3
.14
)
0.
99
12
1.
46
 (0
.39
, 5
.37
)
0.
57
42
1.
06
 (0
.48
, 2
.35
)
0.
89
*
A
dju
ste
d f
or 
ag
e, 
sit
e, 
rac
e, 
ge
nd
er,
 B
BD
, e
thn
ici
ty,
 nu
mb
er 
of 
pri
or 
UT
Is,
 re
cen
t a
nti
bio
tic
 us
e, 
an
d f
ev
er.
C-
sta
tis
tic
 fo
r n
ar
ro
w
 sp
ec
tru
m
 a
nt
ib
io
tic
s, 
1s
t  g
en
er
at
io
n 
ce
ph
al
os
po
rin
s, 
tri
m
et
ho
pr
im
 su
lfa
m
et
ho
xa
zo
le
, n
itr
of
ur
an
to
in
, a
nd
 a
m
ox
ic
ill
in
 w
er
e 
0.
63
, 0
.6
1,
 0
.6
6,
 0
.7
0,
 an
d 
0.
62
 re
sp
ec
tiv
el
y.
J Pediatr. Author manuscript; available in PMC 2017 April 01.
